Next Article in Journal
Effects of Hyperbaric Oxygen Therapy in Children with Severe Atopic Dermatitis
Next Article in Special Issue
Ex-Vivo Pharmacological Defatting of the Liver: A Review
Previous Article in Journal
Characteristics and Detection Rate of SARS-CoV-2 in Alternative Sites and Specimens Pertaining to Dental Practice: An Evidence Summary
Previous Article in Special Issue
From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—New Terminology in Pediatric Patients as a Step in Good Scientific Direction?

Natural History of NAFLD

Institut de Cardiométabolisme et Nutrition, Hôpital Pitié Salpetrière, Assistance Publique Hôpitaux de Paris, 75013 Paris, France
Author to whom correspondence should be addressed.
Academic Editors: Jérémie Gautheron and Vlad Ratziu
J. Clin. Med. 2021, 10(6), 1161;
Received: 18 February 2021 / Accepted: 25 February 2021 / Published: 10 March 2021
The epidemiology and the current burden of chronic liver disease are changing globally, with non-alcoholic fatty liver disease (NAFLD) becoming the most frequent cause of liver disease in close relationship with the global epidemics of obesity, type 2 diabetes and metabolic syndrome. The clinical phenotypes of NAFLD are very heterogeneous in relationship with multiple pathways involved in the disease progression. In the absence of a specific treatment for non-alcoholic steatohepatitis (NASH), it is important to understand the natural history of the disease, to identify and to optimize the control of factors that are involved in disease progression. In this paper we propose a critical analysis of factors that are involved in the progression of the liver damage and the occurrence of extra-hepatic complications (cardiovascular diseases, extra hepatic cancer) in patients with NAFLD. We also briefly discuss the impact of the heterogeneity of the clinical phenotype of NAFLD on the clinical practice globally and at the individual level. View Full-Text
Keywords: fatty liver; fibrosis; metabolic syndrome; insulin resistance fatty liver; fibrosis; metabolic syndrome; insulin resistance
Show Figures

Figure 1

MDPI and ACS Style

Pais, R.; Maurel, T. Natural History of NAFLD. J. Clin. Med. 2021, 10, 1161.

AMA Style

Pais R, Maurel T. Natural History of NAFLD. Journal of Clinical Medicine. 2021; 10(6):1161.

Chicago/Turabian Style

Pais, Raluca, and Thomas Maurel. 2021. "Natural History of NAFLD" Journal of Clinical Medicine 10, no. 6: 1161.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop